Term
|
Definition
- suppressed immune system
- impaired vascular responses
- hyperreactive platelets and coagulation
- inflammation
- increased oxidative stress
|
|
|
Term
Proposed Benefits of Insulin |
|
Definition
- Inhibits lipolysis
- Inhibits inflammatory growth factors
- Enhances vasodilation by stimulating endothelial nitric oxide
- Inhibits proinflammatory cytokines
|
|
|
Term
|
Definition
|
|
Term
Glycemic Goals in Non-ICU |
|
Definition
Preprandial: < 140 mg/dL
Random: < 180 mg/dL |
|
|
Term
"Sliding Scale Insulin": What it is, Disadvantages |
|
Definition
Usually refers to use of regular insulin, dosed based on BG, without any scheduled insulin
Disadvantages:
- Ineffective for hyperglycemia when used as monotherapy
- Gives no incentive to adjust scheduled therapy
- Usually not individualized dosing
- Reactive approach rather than proactive
- Often leads to fluctuation of BG levels
|
|
|
Term
Continuous IV Insulin Infusion: Advantages |
|
Definition
- Most effective in achieving pre-specified BG levels
- Allows rapid dosing adjustment
- Has been shown to decrease mortality and morbidity in some studies
|
|
|
Term
Which insulin is used for Continuous IV Insulin Infusion (CIII) in the inpatient setting? |
|
Definition
|
|
Term
Continuous IV Insulin Infusion: Disadvantages |
|
Definition
- Very labor intensive (requires q 1-2 hr glucose monitoring)
- Increased risk of hypoglycemia
|
|
|
Term
Indications for CIII therapy |
|
Definition
- Critical Illness
- Hyperglycemic Crisis
- Preoperative, intraoperative, and postoperative care
- Post heart surgery
- Post organ transplantation
- Cardiogenic shock
- High dose glucocorticoid therapy
- Prolonged NPO in type 1 diabetes
|
|
|
Term
Transition from CIII to SubQ |
|
Definition
Begin transition to SubQ when patients begin to eat regular meals or transferred to lower intensity care
- Daily SubQ requirements: Approx. 75-80% of total daily IV
- 40-50% of daily SubQ dose should be basal
- 50-60% of daily SubQ dose should be prandial, divided among the meals
IV insulin has short half-life (0.5-1 hr), therefore first dose of SubQ insulin should be administered before DCing IV insulin |
|
|
Term
When should intermediate or long acting insulin be administered before IV insulin is discontinued? |
|
Definition
2-3 hours prior to discontinuation of IV insulin |
|
|
Term
When should combination of basal and prandial insulin be administered before IV insulin is discontinued? |
|
Definition
Basal insulin can be initiated at any time of the day
Administer short or rapid acting insulin 1-2 hrs prior to discontinuing IV infusion |
|
|
Term
When should short acting or rapid acting insulin be administered before IV insulin is discontinued? |
|
Definition
Administer 1-2 hrs prior to discontinuation of IV insulin |
|
|
Term
Prevention of Hypoglycemia in the inpatient setting |
|
Definition
- Pay attention to changes in patient's nutritional status and/or medications
- Ensure a hypoglycemic protocol is in place
- Treat mild hypoglycemia promptly
- Less aggressive dosing in certain patients (increased insulin sensitivity, decreased insulin clearance, diminished glycogen stores)
|
|
|
Term
Follow up upon discharge: hyperglycemic patients with prior DM |
|
Definition
If A1C is elevated upon admission, preadmission regimens need to be revised |
|
|
Term
Follow up upon discharge: hyperglycemic patients without prior DM |
|
Definition
- A1C should be used to differentiate between stress hyperglycemia and undiagnosed DM
- Patient with newly diagnosed DM should receive appropriate education and follow up
- Patients with stress hyperglycemia still need appropriate follow up with a physician
|
|
|
Term
Pathogenesis of DKA: Causes |
|
Definition
- Absolute deficiency of insulin OR
- Insufficient insulin coupled with increased counterregulatory stress hormones
|
|
|
Term
Pathogenesis of DKA: Consequences |
|
Definition
- hyperglycemia -> glucosuria -> osmotic diuresis -> dehydration and loss of Na+ and K+
- increased lipolysis -> increased FFA -> increased ketone bodies -> increased ketonemia and metabolic acidosis
- Evolves over a short period of time (< 24 hrs)
|
|
|
Term
Pathogenesis of HHS: Causes |
|
Definition
- Insufficient insulin AND Insulin resistance
|
|
|
Term
Pathogenesis of HHS: Consequences |
|
Definition
- Residual insulin is sufficient enough to inhibit lipolysis therefore minimizing ketosis, but not hyperglycemia
- Hyperglycemia -> glucosuria -> osmotic diuresis -> severe dehydration (hyperosmolality) -> loss of electrolytes and impaired renal function (eventually less excretion of glucose and accumulation)
- Reduction in urinary excretion of glucose leads to more severe hyperglycemia than in DKA
- Evolves over days and weeks
|
|
|
Term
Major Components of DKA and HHS |
|
Definition
- Hyperglycemia (HHS > DKA)
- Dehydration (HHS > DKA)
- Electrolyte imbalance
- Consistent features (metabolic acidosis in HKA, hyperosmolality in HHS)
|
|
|
Term
Electrolyte Imbalance in DKA and HHS: Sodium |
|
Definition
- Decreased Na and H2O reabsorption and increased urinary Na loss lead to a net loss of total body Na
- Need to correct Na based on glucose level before accessing total Na deficit
|
|
|
Term
Electrolyte Imbalance in DKA and HHS: Potassium |
|
Definition
- Dehydration and acidosis (DKA) cause shifting K out of cells
- Insulinopenia leads to impaired K entry into cells
- Increased K in ECF leads to increase urinary loss
|
|
|
Term
Precipitating Factors for DKA or HHS |
|
Definition
- Infection (by far)
- Inappropriate insulin therapy
- New-onset of diabetes mellitus
- CVD (heart attack, stroke)
- Pregnancy
- Trauma
- Hyperthyroidism
- Pancreatitis
- Drugs (corticosteroids, sympathomimetics)
|
|
|
Term
Clinical Presentation of DKA or HHS: Symptoms and Signs |
|
Definition
Symptoms:
- history of polyuria, polydipsia, weight loss
- N/V, abdominal pain
- fruity odorous breath (DKA)
- weakness and muscle cramps
- altered mental status
Signs:
- dehydration
- hyperventilation
- coma (more frequent in HHS)
|
|
|
Term
Laboratory Evaluation of HHS and DKA |
|
Definition
- Fingerstick
- Chemistry panel
- Urinanalysis
- Arterial blood gas
- Serum osmolality
- Serum ketone and acetone levels
- CBC and cultures if infection is suspected
- EKG if hypokalemic
- A1C to determine acute episode or poor control
|
|
|
Term
|
Definition
Risk of mortality increases in the very young or very old
Negative prognostic factors:
- hypotension
- hypothermia
- coma
|
|
|
Term
Correction of hyperglycemia |
|
Definition
- continuous IV insulin infusion
- if plasma glucose does not fall by 50-75 mg/dL in the first hr, increase infusion rate every hour until steady decline is reached
Maintenance insulin infusion when plasma glucose reaches 200 in DKA or 300 in HHS
- decrease insulin drip and add dextrose to IV fluids
- adjust infusion rate and dextrose amount to maintain 150-200 until DKA resolves or 250-300 until HHS resolves
|
|
|
Term
At what value of K+ should insulin not be initiated? |
|
Definition
|
|
Term
Correction of hyperglycemia if rapid-acting insulin is used |
|
Definition
- Rapid acting insulin may be used in mild DKA
- Administer bolus dose then q 1-2 hr injections to achieve glucose around 250 mg/dL
- Dose is then adjusted until DKA resolves
- No differences in efficacy compared to CIII
- Allows treatment on general medicine floor or ED which cuts cost
|
|
|
Term
Correction of dehydration |
|
Definition
- Need repletion of both intravascular and extravascular volume
- Use crystalloids
- 0.9% NaCl should be used
- Subsequent fluid depends on serum Na+ concentration:
If normal or elevated: 0.45% NaCl
If low: 0.9% NaCl
- When plasma glucose reach 200 mg/dL in DKA or 300 mg/dL in HHS, switch to D5W 0.45% NaCl
- Infusion rate must be adjusted for cardiac and renal dysfunction
- Monitor BP and I/O to better assess fluid status
|
|
|
Term
Correction of Electrolytes |
|
Definition
Sodium (replaced adequately with fluid replacement)
Potassium
- Goal ~ 4-5 mEq/L
- Usually depleted due to urinary loss but serum concentration may be low, normal, or high
- Replacement dose depends on serum K level
- Low (< 3.3): treatment immediately, hold insulin
- Normal (3-5.2): treat while patient is on insulin
- High (> 5.2): no replacement until level drops and recheck q 2hrs
- Must consider renal function
|
|
|
Term
Correction of Metabolic Acidosis |
|
Definition
- Acidosis will correct with insulin therapy
- Sodium bicarb may be necessary only in severe acidosis (pH < 6.9) -> treat with bicarb and K until pH > 7.0
|
|
|